Global GLP-1 Agonists for Obesity Market Growth 2024-2030

Global GLP-1 Agonists for Obesity Market Growth 2024-2030

GLP-1 (glucagon-like peptide-1) agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with Type 2 diabetes. Some GLP-1 agonists have been approved to help treat obesity. GLP-1 agonists have been shown to be effective in promoting weight loss in preclinical and clinical studies.

The global GLP-1 Agonists for Obesity market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “GLP-1 Agonists for Obesity Industry Forecast” looks at past sales and reviews total world GLP-1 Agonists for Obesity sales in 2023, providing a comprehensive analysis by region and market sector of projected GLP-1 Agonists for Obesity sales for 2024 through 2030. With GLP-1 Agonists for Obesity sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world GLP-1 Agonists for Obesity industry.

This Insight Report provides a comprehensive analysis of the global GLP-1 Agonists for Obesity landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on GLP-1 Agonists for Obesity portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global GLP-1 Agonists for Obesity market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for GLP-1 Agonists for Obesity and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global GLP-1 Agonists for Obesity.

United States market for GLP-1 Agonists for Obesity is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for GLP-1 Agonists for Obesity is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for GLP-1 Agonists for Obesity is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key GLP-1 Agonists for Obesity players cover Novo Nordisk, Eli Lilly, Huadong Medicine, Shanghai Benemae Pharmaceutical Corporation, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of GLP-1 Agonists for Obesity market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Semaglutide
Tirzepatide
Liraglutide
Benaglutide

Segmentation by Application:
Hospital Pharmaty
Retail Pharmaty
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
Eli Lilly
Huadong Medicine
Shanghai Benemae Pharmaceutical Corporation

Key Questions Addressed in this Report

What is the 10-year outlook for the global GLP-1 Agonists for Obesity market?

What factors are driving GLP-1 Agonists for Obesity market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do GLP-1 Agonists for Obesity market opportunities vary by end market size?

How does GLP-1 Agonists for Obesity break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.